Q1 2025 Neogenomics Inc Earnings Call Transcript
Key Points
- NeoGenomics Inc (NEO) reported a solid start to the year with revenues of $168 million and adjusted EBITDA of $7.1 million, marking the seventh consecutive quarter of positive adjusted EBITDA.
- Clinical testing volumes increased by 8% compared to the previous year, with a 3% increase in revenue per test.
- The acquisition of Pathline is expected to expand capabilities and accelerate growth, contributing to incremental top-line revenue this year.
- NeoGenomics Inc (NEO) launched five new NGS products, which now account for 22% of total clinical revenue, demonstrating strong market penetration.
- The company is expanding its commercial resources, with approximately 140 salespeople, to drive market penetration into community oncology and support new product launches.
- The non-clinical business, which accounts for around 10% of total revenue, is facing macroeconomic challenges, including reduced pharma and biotech spending.
- Recent tariffs and potential cuts in NIH funding are anticipated to result in reduced R&D spending across the non-clinical customer base.
- The Pathline acquisition is expected to lower average unit price (AUP), adjusted gross margins, and adjusted EBITDA for the remainder of 2025.
- There is heightened uncertainty around pharma and biotech spending, which is expected to lead to a decline in pharma revenue this year.
- The integration of Pathline and the validation of NeoGenomics Inc (NEO)'s existing tests in the Pathline lab will take time, with minimal benefit expected this year.
Greetings and welcome to the Neogenomics, first quarter 2025 conference call. At this time, all participants are on a listen-only mode (Operator Instructions)
I will now turn the conference over to your host, Kendra Sweeney, VP of Investor Relations. Now you may begin.
Thank you, Ellie. Good morning, everyone, and welcome to the Neogenomics first quarter 2025 financial results call. With me today to discuss the results are Tony Zook, Chief Executive Officer; Jeff Sherman, Chief Financial Officer; Warren Stone, President and Chief Operating Officer, and Andrew Lukowiak, Chief Innovation Officer.
Additional members of the management team are available for Q&A, including Kareem Saad, Head of Strategy and Transformation, Ali Olivo, General Counsel and Head of Business Development, and Dr. Nate Montgomery, VP of Clinical Services.
This call is being simultaneously webcast, and we will be referring to a slide presentation that has been posted to the investors tab on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
